Sanofi (EPA:SAN)
82.75
+0.46 (0.56%)
At close: Jan 7, 2026
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€554,200
Profits / Employee
€109,957
Market Cap
100.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| emeis Société anonyme | 83,494 |
| Eurofins Scientific SE | 62,696 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 9,901 |
| Virbac | 6,365 |
Sanofi News
- 7 hours ago - BrightInsight's Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence - GlobeNewsWire
- 1 day ago - Enable Injections Announces $30 Million Investment from Sanofi to Accelerate Manufacturing Capabilities - GlobeNewsWire
- 2 days ago - FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Nasdaq
- 2 days ago - Sanofi's (SNY) Tzield Under Priority Review for Type 1 Diabetes - GuruFocus
- 2 days ago - Sanofi’s Tzield accepted for FDA priority review in younger type 1 diabetes patients - Seeking Alpha
- 2 days ago - Sanofi Says FDA Agrees to Review Diabetes Drug Age Range - WSJ
- 2 days ago - FDA Accepts Sanofi's Tzield SBLA Priority Review To Expand Use In Children 1+ For Type 1 Diabetes - Nasdaq
- 2 days ago - Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes - Benzinga